omniture
logo
Search
至本医疗科技（上海）有限公司 () ORIGIMED CO.LTD
Media Room

Latest News

rss

OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science

SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company h...

2021-12-03 17:01 4433
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science

The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China

* The companion diagnostic (CDx) Human Neurotrophic Tyrosine Receptor Kinase ( NTRK) 1/2/3 Genomic...

2021-08-22 09:00 6041
The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China

OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines

* The collaboration will develop an innovative genomic-based clinical treatment platform * The ...

2020-11-11 21:26 7313
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines

Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection

* The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chines...

2020-04-30 10:01 4272
Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection